NCT05895136View on ClinicalTrials.gov

A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Liver CirrhosisDecompensated Cirrhosis of LiverAcute on Chronic Liver Failure (ACLF)
Interventions
DRUG

Human albumin

"Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients.~ATC-Code: B05AA01"

DRUG

Enoxaparin

Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05

DRUG

Standard medical treatment

SMT will be considered non-study medication and is not specified in the protocol.

Trial Locations (9)

10126

RECRUITING

"Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino", Turin

28034

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

40138

RECRUITING

IRCSS Azienda Ospedaliero Universitaria di Bologna Policlinico di Sant'Orsola, Bologna

48149

RECRUITING

Universität Münster, Münster

52074

RECRUITING

Universitätsklinikum Aachen AöR, Aachen

92110

RECRUITING

Hôpital Beaujon, Clichy

08035

RECRUITING

Hospital Universitari Vall d'Hebron-VHIR, Barcelona

08036

RECRUITING

Hospital Clínic de Barcelona-FCRB, Barcelona

NW3 2QG

NOT_YET_RECRUITING

Royal Free Hospital, London

All Listed Sponsors
collaborator

Horizon 2020 - European Commission

OTHER

lead

European Foundation for Study of Chronic Liver Failure

OTHER